

CORRECTION


Correction: Development of ACE2 autoantibodies after SARS-CoV-2 infection

John M. Arthur, J. Craig Forrest, Karl W. Boehme, Joshua L. Kennedy, Shana Owens, Christian Herzog, Juan Liu, Terry O. Harville

In the Discussion section, there is an error in the last sentence of the sixth paragraph. The correct sentence is: First, there could be a competing substance in plasma or serum that causes activation of ACE2 activity. Second, even though the antibodies can recognize ACE2, they may not all inhibit its enzymatic activity. If this is correct, patients represented by the dots farthest to the right on Fig 7 are most likely to develop symptoms of PASC.

Reference

1. Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, et al. (2021) Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLOS ONE 16(9): e0257016. <https://doi.org/10.1371/journal.pone.0257016> PMID: 34478478



OPEN ACCESS

Citation: Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, et al. (2024) Correction: Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS ONE 19(11): e0314426. <https://doi.org/10.1371/journal.pone.0314426>

Published: November 20, 2024

Copyright: © 2024 Arthur et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.